IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience

• Glavni autori: Shany Sherman (Autor), Efrat Solomon Cohen (Autor), Iris Amitay-Laish (Autor), Emmilia Hodak (Autor), Lev Pavlovsky (Autor)
• Format: Knjiga
• Izdano: Medical Journals Sweden, 2019-05-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

Interleukin-17A inhibitors are a promising alternative to tumor necrosis factor-α inhibitors for the treatment of psoriasis. In-class switch has been hardly investigated for interleukin-17A inhibitors. We report the experience (2017-2018) of a tertiary medical center with interleukin-17A-inhibitor s...